Urgent Panendoscopy in Patients Presenting With Hematochezia

NCT ID: NCT06985277

Last Updated: 2025-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

188 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-09

Study Completion Date

2028-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gastrointestinal bleeding is a significant emergency condition requiring prompt diagnosis. Current evidence presents a clinical paradox: urgent colonoscopy (within 24 hours) shows no clear benefit in several studies, while urgent video capsule endoscopy (VCE) demonstrates improved detection rates for small bowel bleeding.

This study aims to evaluate a novel approach combining urgent colonoscopy followed by same-day VCE for patients with normal colonoscopy findings. This strategy has not been previously assessed and may improve bleeding source detection while reducing patient preparation burden compared to standard sequential testing. Results will be compared against conventional approaches to determine optimal diagnostic timing for patients presenting with hematochezia

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Gastrointestinal bleeding is a common emergency condition and an important public health issue, as it impacts hospitalization rates and mortality in the population if not properly diagnosed and treated. Currently, GI bleeding is classified into upper GI bleeding, mid GI bleeding, and lower GI bleeding, using the locations accessible by esophagogastroduodenoscopy (EGD) and colonoscopy as the dividing points between the upper, mid and lower GI tracts respectively Patients who present with hematochezia, including passing maroon or bright red blood per rectum, most commonly have lower gastrointestinal bleeding. However, patients with mid or upper gastrointestinal bleeding can also present with hematochezia if bleeding is severe. Thus, colonoscopy is often the first diagnostic test in these patients, able to identify a bleeding source in 68-79% of cases. If no bleeding site is found on colonoscopy, esophagogastroduodenoscopy is then performed, revealing a bleeding lesion in 1.3-15% of patients depending on study population. Those without an identified bleeding site on either colonoscopy or EGD are labeled as potential small bowel bleeders (PSBB). Current guidelines recommend video capsule endoscopy (VCE) in PSBB, since it can detect bleeding sites in 60-70% of these patients.

While the above diagnostic approach is widely accepted, the optimal timing for endoscopic evaluation remains controversial with conflicting study results. Several randomized controlled trials (RCTs) and observational studies have reported higher diagnostic yields and treatment rates when colonoscopy is performed within 24 hours of presentation. Particularly in diverticular bleeding, early colonoscopy enables localization and treatment to prevent rebleeding, since delayed colonoscopy may miss active bleeding once it has spontaneously stopped. However, three RCTs did not show a benefit of urgent colonoscopy. A 2020 meta-analysis also found no improvement in diagnostic yield with urgent colonoscopy in suspected lower GI bleeding. Current guidelines from the American Gastroenterological Association in 2023 also do not recommend urgent colonoscopy. Of note however, in the largest RCT by Niikura et al, the control group underwent colonoscopy at a mean of 41 hours after presentation. The small difference in timing may explain the lack of difference seen between groups.

In addition to timing of colonoscopy, timing of video capsule endoscopy (VCE) also appears to impact diagnostic yields in potential small bowel bleeders. A retrospective cohort study of 94 patients found that urgent VCE within 48 hours of admission increased the diagnosis of small bowel bleeding sources to 66%. A 2022 meta-analysis also showed that early VCE after bleeding increases lesions detection in the small bowel by 4.4-fold.

In summary, urgent colonoscopy does not appear beneficial but urgent VCE increases diagnostic yields in patients presenting with hematochezia. This poses a conflict since urgent VCE necessitates preceding urgent colonoscopy. Thus, this study aims to determine if an approach utilizing urgent colonoscopy within 24 hours followed immediately by same-day VCE in cases of normal colonoscopy can improve bleeding source detection compared to the standard sequential approach. This strategy has not been evaluated before. Additional benefits include reducing bowel preparation requirements for patients. Outcomes will be compared to a group undergoing standard sequential evaluation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lower Gastrointestinal Bleeding Small Bowel Bleeding

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Urgent colonoscopy with urgent VCE group

Intervention Arm : Urgent colonoscopy with urgent VCE group :

Patients will undergo colonoscopy within 24 hours of diagnosed lower gastrointestinal bleeding. If no bleeding source is identified on colonoscopy or presumed diverticular bleeding cases, esophagogastroduodenoscopy (EGD) followed by same-session video capsule endoscopy (VCE) will be performed immediately

Group Type EXPERIMENTAL

Urgent endoscopy strategy

Intervention Type DIAGNOSTIC_TEST

Patients will undergo colonoscopy within 24 hours of diagnosed lower gastrointestinal bleeding. If no bleeding source is identified on colonoscopy or presumed diverticular bleeding cases, esophagogastroduodenoscopy (EGD) followed by same-session video capsule endoscopy (VCE) will be performed immediately

Standard colonoscopy with standard VCE group

Control Arm : Standard colonoscopy with standard VCE group :

Patients will undergo colonoscopy within 24-48 hours after diagnosed lower gastrointestinal bleeding. If no bleeding source is identified on colonoscopy or presumed diverticular bleeding cases, esophagogastroduodenoscopy (EGD) will be performed immediately. If EGD shows no bleeding source, video capsule endoscopy (VCE) will be performed within 24 hours of the preceding endoscopies

Group Type EXPERIMENTAL

Standard colonoscopy with standard VCE group

Intervention Type DIAGNOSTIC_TEST

Patients will undergo colonoscopy within 24-48 hours after diagnosed lower gastrointestinal bleeding. If no bleeding source is identified on colonoscopy or presumed diverticular bleeding cases, esophagogastroduodenoscopy (EGD) will be performed immediately. If EGD shows no bleeding source, video capsule endoscopy (VCE) will be performed within 24 hours of the preceding endoscopies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Urgent endoscopy strategy

Patients will undergo colonoscopy within 24 hours of diagnosed lower gastrointestinal bleeding. If no bleeding source is identified on colonoscopy or presumed diverticular bleeding cases, esophagogastroduodenoscopy (EGD) followed by same-session video capsule endoscopy (VCE) will be performed immediately

Intervention Type DIAGNOSTIC_TEST

Standard colonoscopy with standard VCE group

Patients will undergo colonoscopy within 24-48 hours after diagnosed lower gastrointestinal bleeding. If no bleeding source is identified on colonoscopy or presumed diverticular bleeding cases, esophagogastroduodenoscopy (EGD) will be performed immediately. If EGD shows no bleeding source, video capsule endoscopy (VCE) will be performed within 24 hours of the preceding endoscopies

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years
2. Admission for maroon stool and/or red blood per rectum with or without hemodynamic instability
3. Hemodynamic stabilization after initial fluid resuscitation
4. Correction of any coagulopathy prior to endoscopy
5. Provision of informed consent

Exclusion Criteria

1. Hematemesis or nasogastric lavage showing coffee ground material/blood
2. Persistent hemodynamic instability prior to colonoscopy
3. Hospitalization in the preceding 14 days
4. Contraindications to endoscopy e.g. severe asthma, cardiac disease
5. Uncorrected coagulopathy
6. Contraindications to bowel preparation with polyethylene glycol
7. Pregnancy
8. Inflammatory bowel disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mahidol University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nonthalee Pausawasdi

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gastroenterology division, Faculty of Medicine, Siriraj Hospital, Mahidol University Bangkok, , Thailand

Bangkok, Bangkok, Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Si265/2024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.